In:
Cancer, Wiley, Vol. 125, No. 13 ( 2019-07), p. 2213-2221
Abstract:
In this randomized phase 2 trial, ziv‐aflibercept does not increase the antitumor activity of first‐line modified folinic acid, fluorouracil, and oxaliplatin 6 (mFOLFOX6) in metastatic esophagogastric cancer. There is increased toxicity observed in the mFOLFOX6/ziv‐aflibercept arm, which results in decreased exposure to mFOLFOX6.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink